Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Cell marker identifies patients more likely to respond to Taxol
December 28th, 2004
Researchers at The University of Texas M.D. Anderson Cancer Center have found a potential predictor of response to the chemotherapy drug Taxol. Taxol is commonly used before or after surgery for stage I-III breast cancers, even though only a subset of women ultimately benefit from this treatment. Patients whose breast cancer cells have lost their ability to express a protein called tau are twice as likely to have a good response to Taxol treatment, the researchers reported December 8, 2004, at the annual San Antonio Breast Cancer Symposium meeting. The finding makes sense because tau promotes the assembly of microtubules, which...
Source: Cancer Weekly (2004-12-28)
|
